Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 6/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.56 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.52 |
| ▸ | CHUK | O15111 | 3/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12192814 | 0.90 | IKBKB (0.54) | IKBKBROCK1ROCK2PRKCZHRH3 | |
| SCHEMBL12192818 | 0.88 | MAOA (0.54) | IKBKBROCK1ROCK2PRKCZHRH3 | |
| SCHEMBL12192834 | 0.87 | IKBKB (0.56) | IKBKBROCK1ROCK2PRKCZHRH3 | |
| SCHEMBL12192816 | 0.87 | IKBKB (0.51) | IKBKBROCK1ROCK2PRKCZHRH3 | |
| SCHEMBL12192815 | 0.86 | HRH3 (0.56) | IKBKBROCK1ROCK2PRKCZHRH3 | |
| SCHEMBL12192828 | 0.86 | ROCK1 (0.61) | IKBKBROCK1ROCK2PRKCZHRH3 | |
| SCHEMBL12192817 | 0.86 | ROCK1 (0.50) | IKBKBROCK1ROCK2PRKCZHRH3 | |
| SCHEMBL12192917 | 0.85 | IKBKB (0.60) | IKBKBROCK1ROCK2PRKCZHRH3 | |
| SCHEMBL12192861 | 0.84 | NAMPT (0.55) | IKBKBROCK1ROCK2PRKCZHRH3 | |
| SCHEMBL12192831 | 0.84 | ROCK1 (0.56) | IKBKBROCK1ROCK2PRKCZHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722671-B2 | Isoquinoline derivatives | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8722671-B2 | Isoquinoline derivatives | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8501736-B2 | Isoquinoline derivatives | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501736-B2 | Isoquinoline derivatives | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-20110245248-A1 | ISOQUINOLINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-20110245248-A1 | ISOQUINOLINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| EP-1899322-B1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | EP | disclosed |
| US-20090088429-A1 | Isoquinoline Derivatives | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | US | disclosed |
| US-20090088429-A1 | Isoquinoline Derivatives | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | US | disclosed |
| WO-2007000240-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245248-A1 | ISOQUINOLINE DERIVATIVES | MYLK2, MYLK, RHOT2 | IKBKB 866/4885ROCK1 7/4885ROCK2 5/4885 |
| US-20090088429-A1 | Isoquinoline Derivatives | MYLK2, MYLK, RHOT2 | IKBKB 866/4885ROCK1 7/4885ROCK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.